Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02777385
Title Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Pittsburgh
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.